The Microenvironment of Lung Cancer and Therapeutic Implications.
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Advances in experimental medicine and biology, December 2015
Mittal, Vivek, El Rayes, Tina, Narula, Navneet, McGraw, Timothy E, Altorki, Nasser K, Barcellos-Hoff, Mary Helen, Vivek Mittal, Tina El Rayes, Navneet Narula, Timothy E. McGraw, Nasser K Altorki, Mary Helen Barcellos-Hoff, McGraw, Timothy E.
Aamir Ahmad, Shirish M. Gadgeel
The tumor microenvironment (TME) represents a milieu that enables tumor cells to acquire the hallmarks of cancer. The TME is heterogeneous in composition and consists of cellular components, growth factors, proteases, and extracellular matrix. Concerted interactions between genetically altered tumor cells and genetically stable intratumoral stromal cells result in an "activated/reprogramed" stroma that promotes carcinogenesis by contributing to inflammation, immune suppression, therapeutic resistance, and generating premetastatic niches that support the initiation and establishment of distant metastasis. The lungs present a unique milieu in which tumors progress in collusion with the TME, as evidenced by regions of aberrant angiogenesis, acidosis and hypoxia. Inflammation plays an important role in the pathogenesis of lung cancer, and pulmonary disorders in lung cancer patients such as chronic obstructive pulmonary disease (COPD) and emphysema, constitute comorbid conditions and are independent risk factors for lung cancer. The TME also contributes to immune suppression, induces epithelial-to-mesenchymal transition (EMT) and diminishes efficacy of chemotherapies. Thus, the TME has begun to emerge as the "Achilles heel" of the disease, and constitutes an attractive target for anti-cancer therapy. Drugs targeting the components of the TME are making their way into clinical trials. Here, we will focus on recent advances and emerging concepts regarding the intriguing role of the TME in lung cancer progression, and discuss future directions in the context of novel diagnostic and therapeutic opportunities.
|Members of the public||2||100%|
|Readers by professional status||Count||As %|
|Student > Bachelor||14||20%|
|Student > Ph. D. Student||13||19%|
|Student > Master||9||13%|
|Student > Doctoral Student||5||7%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||23||33%|
|Biochemistry, Genetics and Molecular Biology||10||14%|
|Agricultural and Biological Sciences||5||7%|
|Pharmacology, Toxicology and Pharmaceutical Science||3||4%|